Based in the United States, Bond Biosciences is a startup.
Bond Biosciences is a clinical-stage biopharmaceutical company developing non-absorbed oral therapeutics that bind excess ions in the gastrointestinal tract to treat or prevent ion-related diseases, including iron overload caused by hereditary hemochromatosis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.